Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADC-AVP20
- Development stage
- Unknown
- Lead developer
- Avipep
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
ADC-AVP20 is a preclinical-stage Avibody-drug conjugate (ADC) being developed by Avipep for undisclosed therapeutic indications. Built on Avipep's proprietary Avibody™ platform, the candidate consists of a small, stable, bivalent antibody-derived fragment (Avibody) conjugated to a cytotoxic payload. Avibodies are designed to offer superior biodistribution and rapid, deep tumor penetration compared to conventional full-length IgG antibodies, while clearing quickly from systemic circulation to minimize off-target toxicities. The specific target antigen and payload of ADC-AVP20 remain undisclosed.
Beyond the preview
Go deeper on ADC-AVP20.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADC-AVP20.